Replies to post #401193 on Anavex Life Sciences Corp (AVXL)

[sage4]

You probably meant $1249, not $1849 which doesn't really matter at this point.
But it's a half of Jesse's estimation which is unthinkable for me now anyways:
The article below was written by him before CTAD 2022 but he still seems to think a possibility of A273 available for patients this year.

If Alzheimer’s disease is approved in 2023, the company could see potential peak revenues of $17-24B annually (mid-valuation). With a P/E of 21.57 and minimal additional dilution, the share price would exceed $2,480 in the U.S. alone. Rett Syndrome peak sales alone could cause the share price to exceed $700 in similar circumstances.

@xxxxxx, Probably within the next 12 months.

https://www.sotcanalytics.com/home

Thank you ALL!